Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03348163 · ClinicalTrials.gov registry record · Phase 4
(mo)BETTA Trial in Transwomen for Optimization of ART
A Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
- Terminated
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT03348163 is a Phase 4 study that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 26 participants.
The verdict
NCT03348163, a Phase 4 study, was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of a new HIV medication, bictegravir plus emtricitabine plus tenofovir alafenamide (B/FTC/TAF, 3 HIV medications combined into one pill) in HIV-infected transgender women (TW).
Interventions
- DRUG B/FTC/TAF
- DRUG Current ART
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-06-06 |
| Est. Completion | 2020-12-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03348163
The ClinicalTrials.gov registry entry for NCT03348163 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which B/FTC/TAF is the first listed.
NCT03348163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03348163 about?
NCT03348163 is a clinical study titled "(mo)BETTA Trial in Transwomen for Optimization of ART". The purpose of this study is to determine the safety and tolerability of a new HIV medication, bictegravir plus emtricitabine plus tenofovir alafenamide (B/FTC/TAF, 3 HIV medications combined into one pill) in HIV-infected transgender women (TW).
What is the current status of trial NCT03348163?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2018-06-06. Estimated completion is 2020-12-15.
What interventions are being tested in trial NCT03348163?
The interventions under investigation include: B/FTC/TAF (DRUG), Current ART (DRUG).
Who is sponsoring clinical trial NCT03348163?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.